Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Transition to IRD maintenance after DRD induction significantly deepens response in transplant-ineligible NDMM: A prospective multicenter study

View Full Paper
Ask AI
Bookmark
Share

Authors

MWMengzhen WangYZYan ZhuJLJunnan Li

Discussion

Loading...

Member takes

Overview

Prospective multicenter study shows ird maintenance improves efficacy and quality of life in patients with transplant-ineligible ndmm, suggesting a viable strategy to prolong treatment.

Key Points

  • Patients on ird maintenance showed a significant increase in response rates, with 60.4% achieving CR/sCR after transitioning from DRd.
  • Grade ≥3 neutropenia occurred in 8% and infections affected 20% of participants, highlighting safety concerns.
  • This prospective multicenter study enrolled 53 transplant-ineligible NDMM patients transitioning from DRd to IRd maintenance treatment.
  • Overall, findings underscore the potential of IRd maintenance to improve treatment duration and patient quality of life in this vulnerable population.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da9ahttps://doi.org/10.1182/blood-2025-4059
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world experience with first-line regimens in transplant-ineligible patients with multiple myeloma2025
  2. 2Transition to ixazomib-based maintenance following daratumumab-based induction for continuous therapy in newly diagnosed multiple myeloma2025
  3. 3Isatuximab (Isa) plus lenalidomide (R), Bortezomib (V), and dexamethasone (d) (Isa-RVd) as induction therapy in transplant-eligible patients (pts) with newly diagnosed multiple myeloma (NDMM): Primary analysis of parallel phase 2 studies by the Dana-Farber Cancer Institute (DFCI) and Cancer Trials Ireland (CTI)2025
  4. 4Efficacy and safety of daratumumab plus carfilzomib-based induction/consolidation/maintenance therapy with autologous stem cell transplantation in transplant-eligible ultra high-risk newly diagnosed multiple myeloma: Preliminary results2025
  5. 5Iberdomide plus daratumumab and dexamethasone (IberDd) in patients with newly diagnosed multiple myeloma by renal function: A subgroup analysis of the CC-220-MM-001 trial2025 · 2 citations